Business
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference. Cognition VP of research, Mary Hamby, PhD presents findings from an unbiased proteomic analysis of combined datasets from the first cohort of the Phase 2 SHINE study and the completed Phase 1b SPARC study, both conducted in mild-to-moderate Alzheimer's disease patients and similarly treated with either CT1812 or placebo. This meta-analysis revealed that CT1812 treatment was associated with statistically significant changes in biomarkers associated with: synaptic function,amyloid biology,and neuroinflammation. Importantly, these changes in key biomarkers were replicated across studies, and had similar directionality and degree of change. In this conversation, Dr. Charlotte Teunissen moderates a discussion on interpretation of these findings and their relevance to the CT1812 mechanism of action with two leading experts in biomarker development. Episode 5: “Exploring the Effects of CT1812 on Alzheimer’s Disease Processes: Proteomics and Pathways of Neurodegeneration” features: Charlotte Teunissen, PhD - Professor of Clinical Neurochemistry at Amsterdam University Medical CenterNicholas Seyfried, PhD - Professor of Biochemistry and Neurology at Emory University School of Medicine and Director of the Emory Integrated Proteomics CoreHenrik Zetterberg, MD, PhD - Professor of Neuroscience at Gothenburg University and Group Leader of the UK Dementia Research Institute Cognition Therapeutics welcomes comments, questions and feedback on this and other Conversations episodes which may be submitted at [email protected]. We’d love to hear your thoughts! About Cognition Therapeutics, Inc.Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD)....